Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bleomycin
Drug ID BADD_D00280
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status approved; investigational
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D07535
MeSH ID D001761
PubChem ID 5460769
TTD Drug ID D06UVD
NDC Product Code 0143-9241; 69097-364; 0703-3155; 0143-9240; 16714-908; 61703-332; 61703-323; 16714-886; 0409-0332; 70121-1567; 0409-0323; 0703-3154
UNII 40S1VHN69B
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H84N17O21S3+
CAS Registry Number 11056-06-7
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aggression19.05.01.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Arteritis24.12.02.001--Not Available
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Bladder pain20.02.02.001--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cerebral arteritis24.12.02.002; 17.08.02.004--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.002--Not Available
Chest X-ray normal13.19.02.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Cough22.02.03.001--
Cystitis11.01.14.001; 20.03.02.002--
Cystitis haemorrhagic20.03.02.003--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001--Not Available
Extravasation08.01.03.008--Not Available
Febrile neutropenia08.05.02.004; 01.02.03.002--
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene